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ABSTRACT
Objective: To assess retrospectively the ocular changes in children and adolescents with juvenile systemic lupus erythe-
matosus (JSLE) in a tertiary pediatric rheumatology service. Methods: This study assessed 117 JSLE patients (85.5% 
female, 60.7% non-Caucasian), who met at least four criteria of the 1997 SLE classiﬁ cation of the American College 
of Rheumatology. Their mean age was 10.4 years, and their mean time of disease progression was 5.4 years. A protocol 
containing clinical and demographic data, ophthalmologic complaints and changes, age of onset, duration of medication 
use, and cumulative medication dose was applied. Results: Of the 117 patients, 24 (20.5%) had ocular changes. Sixteen of 
them had abnormal fundoscopy associated with systemic hypertension and/or use of chloroquine; four had cataract; two 
had glaucoma; and two had cataract and glaucoma. The mean age of ocular change onset was 14.1 years. Patients with 
ocular changes received statistically higher and longer doses of glucocorticoid pulse therapy as compared with patients 
without ocular changes [1.5 (0.4 to 1.6) versus 1 (0.2 to 1.6) mg/kg, P = 0.003; 25.7 (2–99) versus 17.8 (1–114) months, 
P = 0.0001, respectively]. Conclusion: A high prevalence of ocular changes relating mainly to the treatment of JSLE was 
observed. This demonstrates the need for regular ophthalmologic examinations even in asymptomatic patients, aiming at 
the early diagnosis and intervention, and at decreasing the ocular morbidity related to that disease.
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INTRODUCTION
Juvenile systemic lupus erythematosus (JSLE) is a chronic 
multisystem inﬂ ammatory disease, of unknown etiology and 
autoimmune nature, which begins before the age of 18 years, but 
rarely before the age of ﬁ ve years. The disease may be present in 
all races. During childhood, girls are 4.5 times more affected than 
boys.1–4 Of all JSLE cases, 15%–17% develop in the childhood.5,6 
The criteria for SLE classification suggested by the 
American College of Rheumatology7 in 1982 and reviewed 
in 1997 are used for the diagnosis of SLE.8
Several drugs have been used to treat JSLE, mainly gluco-
corticoids, hydroxychloroquine/chloroquine diphosphate and 
immunosuppressive drugs, such as azathioprine, cyclosporine, 
cyclophosphamide, and mycophenolate mofetil. 
Any part of the eye or visual system may be affected by 
thrombotic or inﬂ ammatory processes. The eye disease may 
be asymptomatic or lead to blindness, and there may be no 
relationship between the ophthalmologic manifestations and 
disease activity. Ophthalmologic manifestations of SLE may 
vary from the mucocutaneous disease of the eyelids to the 
retinal vascular disease and neuro-ophthalmic involvement.9–12 
Scleritis, episcleritis, anterior uveitis, and dry eye are some of 
the ophthalmologic disorders in SLE. 
SLE manifestations detected from observation of the eye fun-
dus usually consist of cotton wool spots with or without intraretinal 
hemorrhages, papilledema, retinal hyperemia and edema, which 
may occur even in the absence of intracranial hypertension.13 
Occlusion of large arterioles by spasm and thrombosis has also 
been described, and occurs in association with vasculitis.12 
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In addition to the typical ophthalmologic manifestations of 
the disease, there are those resulting from the use of medica-
tions or from disease complications, such as arterial hyperten-
sion or thromboembolic disease. 
This study aimed at assessing the changes detected on the 
ophthalmologic examination of JSLE patients, and their rela-
tionships with the speciﬁ c treatment for the disease.
MATERIAL AND METHODS
This study assessed the medical records of 117 patients fol-
lowed up from 1994 to 2009 and diagnosed with JSLE in ac-
cordance with the American College of Rheumatology criteria 
for SLE classiﬁ cation of 19827 and reviewed in 1997.8 Their 
clinical and demographic characteristics and their therapy data 
were assessed. The inclusion criteria comprised all patients 
with complete and available medical records, whose disease 
lasted at least six months. A protocol containing clinical and 
demographic data, systemic involvement, associated diseases, 
ophthalmologic complaints and changes, age of onset, dura-
tion of medication use, and cumulative glucocorticoid dose 
was applied.
Disease activity was measured by use of the Systemic Lupus 
Erythematosus Disease Activity Index 2000 (SLEDAI-2K).14 
Cumulative damage of the disease was evaluated by use of the 
Systemic Lupus International Collaborating Clinics/American 
College of Rheumatology damage index for systemic lupus 
erythematosus (SLICC/ACR-DI).15
The patients of this study underwent ophthalmologic 
examination at the department of ophthalmology of the same 
institution every six months. Ophtalmologic examination 
consisted of the visual acuity test, biomicroscopy to evaluate 
the ocular surface, tonometry, and indirect binocular oph-
thalmoscopy. In some cases, when indicated, campimetry 
was performed. 
Patients were considered hypertensive when their medical 
records showed systolic and/or diastolic blood pressure levels 
equal to or greater than p95 of the blood pressure table accord-
ing to gender, height, and age on three or more occasions.16 
The presence of the anticardiolipin antibody was recorded. 
To assess the association between dichotomous variables, 
the chi-square test was used. Continuous variables underwent 
the Kolmogorov-Smirnov test. To compare both groups, 
the Student t test was used for parametric variables, and the 
Mann-Whitney test was used for the non-parametric ones. The 
signiﬁ cance level adopted was 5% (P < 0.05). 
The study was approved by the ethics committee of 
Universidade Federal de São Paulo.
RESULTS
Of the 117 patients evaluated, 85.5% were female and 60.7% 
non-Caucasian. The mean age at the time of evaluation was 
10.4 years. The mean time required for the diagnosis of JSLE 
was 9.9 months, and the mean follow-up time of the disease 
was 5.4 years.
Of the 117 patients, 24 (20.5%) had ocular changes at some 
point of their clinical follow-up as follows: 16 had abnormal 
funduscopy; four had posterior subcapsular cataract; two had 
glaucoma; and two had glaucoma and posterior subcapsular 
cataract. Of those 24 patients, 21 (87.5%) were female and 
16 (66.7%), non-Caucasian. Their mean age at the time of the 
JSLE diagnosis was 11.4 years, and the time required for the JSLE 
diagnosis varied from 1 to 22 months (mean of 4.7 months). 
Patients’ age at the ocular change onset ranged from 5 to 16.2 
years (mean of 14.1 years). 
When the ophthalmologic manifestation was diagnosed, 
the mean SLEDAI-2K was 4.2 (ranging from 0 to 23) and the 
mean SLICC/ACR-DI was 1 (ranging from 0 to 3). 
Clinical and demographic data of patients with and without 
ocular changes are shown in Table 1.
Four out of the 24 patients (16.7%) had ophthalmologic 
complaints as follows: two (8.3%) reported ocular hyperemia; 
Table 1
Clinical and demographic data of JSLE patients (n = 117) with 
or without ocular change 
JSLE
Without 
ocular change
With ocular 
change P
Female gender 79 (84.9%) 21 (87.5%) NS
Non-Caucasian 55 (59.1%) 16 (66.7%) NS
Age on the occasion of ocular
change (years) (minimum-
maximum)
— 14.1 (5–16.2)
Duration of disease (years)
(minimum-maximum)
5 (0.2–14) 5.8 (0.6–13.8) NS
Patients using GC 9 (100%) 24 (100%) 
Maximum GC dose (mg/kg) 1 (0.2–1.6) 1.5 (0.4–1.6) 0.003*
Duration of GC treatment (months) 27.8 (1–107) 29 (3–103) NS
Patients on GC pulse therapy 74 (79.6%) 20 (83.3%) NS
Mean duration of pulse 
therapy (months)
17.8 (1–114) 25.7 (2–99) 0.000§
Patients on chloroquine 93 (100%) 24 (100%) —
Patients on other 
immunosuppressive drugs
66 (70.9%) 13 (54%) NS
Total of patients 93 24 —
GC: glucocorticoid; NS: non-signiﬁ cant (P > 0.05).
*Student t test. §Mann-Whitney test.
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one (4.2%) reported eye pruritus; and one (4.2%) reported a 
pricking sensation in the eyes. 
Of the 24 patients with ocular changes, seven (29.1%) had 
positive anticardiolipin antibody titers as follows: two had 
cataract; one had glaucoma; one had papilledema; and three had 
macula change. None of those patients had antiphospholipid 
antibody syndrome. 
The age of cataract onset ranged from 11 years to 17.7 
years (mean of 13.8 years). The six patients with cataract used 
glucocorticoids from 10 to 84 months (mean of 45 months). 
Such patients received pulse therapy with methylprednisolone 
at the dosage of 30 mg/kg/day for three days, for a period rang-
ing from 2 to 99 months. The cumulative glucocorticoid dose 
ranged from 35.5 g to 97.3 g. The age at which glucocorticoid 
use started varied from 7.9 years to 14.3 years (mean of 13.8 
years). 
The age of glaucoma onset varied from 10.9 years to 14.2 
years (mean of 12.3 years). Patients with that complication used 
glucocorticoid from three to 53 months (mean of 21 months). 
The cumulative glucocorticoid dose ranged from 5 g to 40.5 g. 
One patient had irreversible unilateral vision loss secondary 
to corticosteroid-induced glaucoma.
The 24 patients with any ocular change were using gluco-
corticoid and hydroxychloroquine/chloroquine diphosphate 
on the occasion of the ocular change. 
Patients with ocular changes received statistically higher 
and longer doses of glucocorticoid pulse therapy as compared 
with patients without ocular changes [1.5 (0.4–1.6) versus 1 
(0.2–1.6) mg/kg, P = 0.003; 25.7 (2–99) versus 17.8 (1–114) 
months, P = 0.0001, respectively]. No statistic difference was 
observed in the other parameters evaluated (Table 1). 
Eight (50%) out of the 16 patients with abnormal fundus-
copy had macula change associated with chloroquine use as 
follows: three were on hydroxychloroquine; two on chloro-
quine diphosphate; and three on chloroquine diphosphate and 
hydroxychloroquine afterwards. Those patients used their 
medications from one to ﬁ ve years (mean of 2.7 years). The 
mean age of ocular change onset related to hydroxychloro-
quine/chloroquine diphosphate use was 14.6 years. Three 
patients (37.5%) with macula change (two on chloroquine 
diphosphate and one on hydroxychloroquine) had to discon-
tinue chloroquine. 
Twelve (50%) of the 24 patients had a diagnosis of systemic 
arterial hypertension. Eight of them were on one or more anti-
hypertensive drugs. Of the hypertensive patients, three (25%) 
had cotton wool spots and papilledema, changes consistent with 
arterial hypertension. Neither retinal vasculitis nor uveitis was 
described in any patient. 
DISCUSSION 
Most studies have described ocular changes related to SLE, 
and more rarely the consequent changes to medications or 
complications of the disease have been described. However, 
publications in pediatrics are scarce.17 A study with 52 JSLE 
patients has reported a 34.6% frequency of ocular changes. 
Of those patients, 61.1% had JSLE for more than one year.17
According to reports in the literature, the prevalence of 
retinal changes resulting from SLE ranges from 3% to 50% 
of adult patients.18,19 In our case series, the frequency of ocular 
changes was lower (20%).
A study has reported an approximate 70% frequency of 
keratoconjunctivitis sicca in patients with SLE.20 We have 
not found that association on biomicroscopy to evaluate the 
ocular surface. 
The ocular involvement has often been a late manifestation, 
because it has mostly resulted from complications of the treat-
ment leading to cataract, glaucoma, and abnormal funduscopy. 
We found ocular changes resulting exclusively from the 
use of glucocorticoid or chloroquine or consequent to systemic 
arterial hypertension. Biomicroscopy was routinely performed 
in all patients, but no uveitis was found. In the literature, uveitis 
has been reported as a rare ﬁ nding.13 
Glaucoma and cataract have been known to be complica-
tions of the treatment with systemic and local glucocorticoids,9 
which suggests that that medication may be involved in the 
genesis of the ocular change.
In severe cases, the ophthalmologic involvement may 
progress to legal blindness. Blindness resulting from previous 
uveitis has been reported in a patient with JSLE, and retinal 
vasculitis secondary to ocular infection by varicella zoster virus 
has been reported in another JSLE patient. The authors have 
concluded that the disease activity and infections may lead to 
those serious ocular sequelae.21 
Chloroquine has been reported as capable of provoking 
retinal toxicity due to retina impregnation. Eight patients had 
abnormal funduscopy compatible with that adverse event. 
However, those abnormalities have been described when the 
drug is used for over ﬁ ve years, which did not happen with 
our patients, who had an earlier retinal change. No patient was 
receiving the drug at doses greater than those recommended. 
Regular ophthalmologic examinations every six months are 
required to early detect those alterations. Three patients on 
chloroquine had to discontinue the drug. 
A study has reported that around 1%–2% of lupus pa-
tients had optic neuritis or ischemia, manifested as progres-
sive visual loss and pale papilla.19 Another study has found 
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5% of changes in the pigmented epithelium of retina.22 We 
found no patient with those changes. Patients with SLE and 
high titers of anticardiolipin antibodies have a greater risk 
of developing occlusive ocular vascular disease.18 Although 
we found seven patients positive for that antibody, none had 
thromboembolic disease. 
In order to assess a greater population, multicenter studies 
are necessary to evaluate ocular changes in JSLE patients. 
Thus, risk factors or possible associations between those ocular 
changes and demographic data, disease activity and severity, 
cumulative damage, antiphospholipid antibodies, and treatment 
can be analyzed. 
This study showed a high prevalence of abnormal fundus-
copy related mainly to the treatment of SLE. In conclusion, 
ophthalmologic examinations every six months are required 
even in asymptomatic SLE patients or those without associated 
diseases, aiming at the early diagnosis and intervention and at 
decreasing the disease-related ocular morbidity.
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